TriActive trials
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash initiates pivotal trial enrollment for the ProGuard update to its TriActive embolic protection system in carotid stenting procedures. The Exton, Pa. firm hopes to complete the 300- to 400-patient multicenter trial to support a 510(k) submission by early 2008. The device is designed to reduce incidence of embolic stroke during carotid artery angioplasty using a balloon protection guidewire, flush catheter and an automated extraction system to remove debris. Kensey Nash says the ProGuard can be used in combination with any currently marketed carotid stent. A pilot trial, completed earlier this year, found no incidence of major stroke or death in 50 patients...
You may also be interested in...
Kensey Nash Exits Embolic Protection To Focus R&D Cash On Biomaterials
Kensey Nash's discontinuation of its embolic protection device business will free-up R&D resources for its biomaterials division, the firm says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.